MA26645A1 - Composes destines au traitement des troubles psychiotriques, neurologiques et physiologiques lies au recepteur de l'orphanine fq - Google Patents

Composes destines au traitement des troubles psychiotriques, neurologiques et physiologiques lies au recepteur de l'orphanine fq

Info

Publication number
MA26645A1
MA26645A1 MA25617A MA25617A MA26645A1 MA 26645 A1 MA26645 A1 MA 26645A1 MA 25617 A MA25617 A MA 25617A MA 25617 A MA25617 A MA 25617A MA 26645 A1 MA26645 A1 MA 26645A1
Authority
MA
Morocco
Prior art keywords
psychiotric
orphanine
neurological
receptor
compounds
Prior art date
Application number
MA25617A
Other languages
English (en)
Inventor
Geo Adam
Andrea Cesura
Francois Jenck
Sabine Kolczewski
Stephan Roever
Juergen Wichmann
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA26645A1 publication Critical patent/MA26645A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA25617A 1998-06-12 1999-06-10 Composes destines au traitement des troubles psychiotriques, neurologiques et physiologiques lies au recepteur de l'orphanine fq MA26645A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98110803 1998-06-12

Publications (1)

Publication Number Publication Date
MA26645A1 true MA26645A1 (fr) 2004-12-20

Family

ID=8232113

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25617A MA26645A1 (fr) 1998-06-12 1999-06-10 Composes destines au traitement des troubles psychiotriques, neurologiques et physiologiques lies au recepteur de l'orphanine fq

Country Status (30)

Country Link
US (1) US6642247B2 (fr)
EP (1) EP0963985B1 (fr)
JP (1) JP3369123B2 (fr)
KR (1) KR100393311B1 (fr)
CN (2) CN1110497C (fr)
AR (1) AR019860A1 (fr)
AT (1) ATE234302T1 (fr)
AU (1) AU752835B2 (fr)
BR (1) BR9902653A (fr)
CA (1) CA2274201C (fr)
CO (1) CO5040061A1 (fr)
CZ (1) CZ291323B6 (fr)
DE (1) DE69905798T2 (fr)
DK (1) DK0963985T3 (fr)
ES (1) ES2194402T3 (fr)
HR (1) HRP990187A2 (fr)
HU (1) HUP9901910A3 (fr)
ID (1) ID23306A (fr)
IL (1) IL130375A0 (fr)
MA (1) MA26645A1 (fr)
NO (1) NO312591B1 (fr)
NZ (1) NZ336226A (fr)
PE (1) PE20000540A1 (fr)
PL (1) PL333693A1 (fr)
PT (1) PT963985E (fr)
SG (1) SG83135A1 (fr)
TR (1) TR199901380A2 (fr)
TW (1) TW434241B (fr)
YU (1) YU26799A (fr)
ZA (2) ZA993853B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0997464B1 (fr) * 1998-10-23 2005-02-16 Pfizer Inc. 1,3,8-Triazaspiro[4,5] decanones utiles comme agonistes du récepteur orl1
US7566728B2 (en) 2002-03-29 2009-07-28 Mitsubishi Tanabe Pharma Corporation Remedy for sleep disturbance
DE102004014296A1 (de) 2004-03-22 2005-10-06 Grünenthal GmbH Substituierte 1,4,8-Triazaspiro[4.5]decan-2-on-Verbindingen
KR100662191B1 (ko) 2004-12-23 2006-12-27 엘지이노텍 주식회사 질화물 반도체 발광소자 및 그 제조방법
CN101622241B (zh) 2007-03-01 2013-05-22 田边三菱制药株式会社 苯并咪唑化合物及其医药用途
TW201016675A (en) 2008-09-16 2010-05-01 Mitsubishi Tanabe Pharma Corp Crystalline benzoimidazole compound and salt thereof
CN109503582A (zh) * 2018-12-17 2019-03-22 上海合全药物研发有限公司 顺式螺[哌啶并-4,1＇-吡咯并[3,4-c]吡咯]-1-甲酸叔丁酯的合成方法
EP4137496A4 (fr) * 2020-05-12 2024-08-21 Beijing Greatway Pharmaceutical Technology Co., Ltd. Composé permettant d'ajuster l'activité du récepteur nmda, composition pharmaceutique et utilisation associées
KR20220022988A (ko) 2020-08-20 2022-03-02 제트스타 주식회사 트랙터용 써레

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63208844A (ja) * 1987-02-26 1988-08-30 Konica Corp 有機着色物質の光褪色防止方法
US5221675A (en) * 1989-12-15 1993-06-22 Abbott Laboratories Aza-spirocyclic compounds that enhance cholinergic neurotransmission
US5534520A (en) * 1990-04-10 1996-07-09 Fisher; Abraham Spiro compounds containing five-membered rings
CA2226058C (fr) * 1997-01-30 2008-01-29 F. Hoffmann-La Roche Ag Derives de substitution en 8 de 1,3,8-triazaspiro[4.5]decan-4-one

Also Published As

Publication number Publication date
EP0963985B1 (fr) 2003-03-12
CN1229377C (zh) 2005-11-30
CN1244528A (zh) 2000-02-16
NO992876D0 (no) 1999-06-11
JP3369123B2 (ja) 2003-01-20
HUP9901910A2 (hu) 2000-04-28
AR019860A1 (es) 2002-03-20
ES2194402T3 (es) 2003-11-16
ZA993853B (en) 1999-12-13
AU752835B2 (en) 2002-10-03
CA2274201C (fr) 2010-02-09
US6642247B2 (en) 2003-11-04
CN1110497C (zh) 2003-06-04
ATE234302T1 (de) 2003-03-15
DK0963985T3 (da) 2003-06-23
IL130375A0 (en) 2000-06-01
KR100393311B1 (ko) 2003-08-02
PT963985E (pt) 2003-06-30
PL333693A1 (en) 1999-12-20
HUP9901910A3 (en) 2001-11-28
PE20000540A1 (es) 2000-07-15
HU9901910D0 (en) 1999-08-30
DE69905798D1 (de) 2003-04-17
DE69905798T2 (de) 2004-02-12
EP0963985A2 (fr) 1999-12-15
YU26799A (sh) 2002-03-18
NO312591B1 (no) 2002-06-03
ID23306A (id) 2000-04-05
ZA993901B (en) 1999-12-13
TR199901380A3 (tr) 2001-01-22
CA2274201A1 (fr) 1999-12-12
KR20000006135A (ko) 2000-01-25
CN1242367A (zh) 2000-01-26
TR199901380A2 (xx) 2001-01-22
NO992876L (no) 1999-12-13
CZ291323B6 (cs) 2003-02-12
BR9902653A (pt) 2000-05-02
CO5040061A1 (es) 2001-05-29
AU3498699A (en) 1999-12-23
EP0963985A3 (fr) 2001-01-24
US20030176701A1 (en) 2003-09-18
CZ203999A3 (cs) 2000-03-15
TW434241B (en) 2001-05-16
NZ336226A (en) 2000-10-27
HRP990187A2 (en) 2000-02-29
JP2000026466A (ja) 2000-01-25
SG83135A1 (en) 2001-09-18

Similar Documents

Publication Publication Date Title
EP1461323A4 (fr) Composes destines au traitement de troubles metaboliques
EP1399171A4 (fr) Composes d'herbes medicinales destines a la prevention et au traitement du diabete
EP0788359A4 (fr) Compositions utiles a la preparation de medicaments destines au traitement de divers troubles refractaires
EP1625207A4 (fr) Composes servant au traitement de l'inflammation, du diabete et de troubles connexes
EP0764026A4 (fr) Administration de pirenzepine, de methyl-scopolamine et d'autres antagonistes des recepteurs muscariniques pour le traitement des troubles du metabolisme des lipides
EP0859637A4 (fr) Compositions destinees au traitement et au diagnostic des problemes de poids, dont l'obesite
EP1252329A4 (fr) Hypocretine et recepteurs d'hypocretine pour la regulation du sommeil et des troubles du sommeil
CH1143977H1 (fr) 2-Oxy-benzoxazine-4-ones destinees au traitement de l'obesite
IL116998A0 (en) Novel indoline compounds processes for their preparation and their use for the treatment of CNS disorders
EP1673376A4 (fr) Traitement des troubles osseux avec des modulateurs de recepteurs d'androgenes selectifs
JO2207B1 (en) Pharmaceutical radiological compounds to diagnose Alzheimer's disease
EP1534696A4 (fr) Composes therapeutiques destines au traitement d'etats dyslipidemiques
MY135838A (en) Methods for the treatment of mental disorders
EP1539136A4 (fr) Composes selectifs des recepteurs ppar alpha destines au traitement de la dyslipidemie et d'autres troubles lipidiques
HUP0201791A3 (en) The use of escitalopram for treatment of neurotic disorders
EP1060748A4 (fr) Medicaments destines aux troubles de l'epithelium corneen
NO932391D0 (no) Angiotensin-ii reseptorantagonister for behandling av hjerterytmeforstyrrelser
GB2361872B (en) Diagnosis of medical disorders
GB9926968D0 (en) Treatment of neurological disorders
MA26643A1 (fr) Nouveaux composes pour la preparation de medicaments pour le traitement de maladies associees au recepteur orphanine fq
IL152688A0 (en) Combination of lipoic acid and c1 donors for the treatment of disorders of the central nervous system
EP1458694A4 (fr) Composes therapeutiques destines au traitement d'etats dyslipidemiques
FR2792199B3 (fr) Utilisation de l'osanetant pour la preparation de medicaments utiles dans le traitement des troubles de l'humeur
EP0979234A4 (fr) Procedes et compositions s'appliquant au diagnostique et au traitement des troubles neuropsychiatriques
FR2774289B1 (fr) Medicament pour le traitement des dereglements de l'apoptose